ZANUBRUTINIB (ZANU) VERSUS BENDAMUSTINE + RITUXIMAB (BR) IN PATIENTS (PTS) WITH TREATMENT‐NAïVE (TN) CLL/SLL: EXTENDED FOLLOW‐UP OF THE SEQUOIA STUDY
Hematological Oncology · 2023-06 · 41 (S2) · 235-238
DOI: 10.1002/hon.3163_154 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hematological Oncology, online erschienen am 09.06.2023. Verfasst von M. Shadman und 34 weiteren Autor:innen. Die Arbeit wurde bisher 13-mal zitiert (Crossref).
Abstract (Originalsprache)
cohort.Rates of atrial fibrillation remained low, and no new safety signals were identified.Zanu continues to be well tolerated over time, with low rates of treatment discontinuation, and remains a valuable treatment option for TN CLL/SLL.
Zitieren
APA
Shadman, M., Munir, T., Roback, T., Brown, J. R., Kahl, B. S., Ghia, P., Giannopoulos, K., Šimkovič, M., Österborg, A., Laurenti, L., Walker, P., Opat, S., Ciepluch, H., Greil, R., Hanna, M., Tani, M., Trněný, M., Brander, D., Flinn, I. W., …, & Jurczak, W. (2023). ZANUBRUTINIB (ZANU) VERSUS BENDAMUSTINE + RITUXIMAB (BR) IN PATIENTS (PTS) WITH TREATMENT‐NAïVE (TN) CLL/SLL: EXTENDED FOLLOW‐UP OF THE SEQUOIA STUDY. Hematological Oncology, 41(S2), 235-238. https://doi.org/10.1002/hon.3163_154
Vancouver
Shadman M, Munir T, Roback T, Brown JR, Kahl BS, Ghia P, et al. ZANUBRUTINIB (ZANU) VERSUS BENDAMUSTINE + RITUXIMAB (BR) IN PATIENTS (PTS) WITH TREATMENT‐NAïVE (TN) CLL/SLL: EXTENDED FOLLOW‐UP OF THE SEQUOIA STUDY. Hematological Oncology. 2023;41(S2):235-238. doi:10.1002/hon.3163_154
BibTeX
@article{Shadman2023,
author = {Shadman, M. and Munir, T. and Roback, T. and Brown, J. R. and Kahl, B. S. and Ghia, P. and Giannopoulos, K. and Šimkovič, M. and Österborg, A. and Laurenti, L. and Walker, P. and Opat, S. and Ciepluch, H. and Greil, R. and Hanna, M. and Tani, M. and Trněný, M. and Brander, D. and Flinn, I. W. and Grosicki, S. and Verner, E. and Tedeschi, A. and Guibert, S. De and Tumyan, G. and Laribi, K. and García, J. A. and Li, J. and Tian, T. and Ramakrishnan, V. and Liu, Y. and Szeto, A. and Paik, J. and Cohen, A. and Tam, C. S. and Jurczak, W.},
title = {ZANUBRUTINIB (ZANU) VERSUS BENDAMUSTINE + RITUXIMAB (BR) IN PATIENTS (PTS) WITH TREATMENT‐NAïVE (TN) CLL/SLL: EXTENDED FOLLOW‐UP OF THE SEQUOIA STUDY},
journal = {Hematological Oncology},
year = {2023},
volume = {41},
number = {S2},
pages = {235--238},
doi = {10.1002/hon.3163_154}
}
EUVIMED